CSIMarket Company Name, Ticker, Industry, else..
 
Tango Therapeutics Inc   (NASDAQ: TNGX)
 
Price: $23.4000 $0.03 0.128%
Day's High: $24.149999618530273 Week Perf: 3.91 %
Day's Low: $ 23.33 30 Day Perf: -8.52 %
Volume (M): 148,301 52 Wk High: $ 34.39
Volume (M$): $ 0 52 Wk Avg: $17.51
Open: $23.72 52 Wk Low: $6.38



 Market Capitalization (Millions $) 3,507
 Shares Outstanding (Millions) 150
 Employees 137
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -124
 Cash Flow (TTM) (Millions $) 118
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tango Therapeutics Inc is a biotechnology company that is focused on developing precise cancer therapies utilizing a next-generation approach. The company leverages the latest advancements in genomics and CRISPR screening technology to identify and target cancer vulnerabilities. Their platform aims to deliver personalized and precise treatments that can overcome drug resistance and improve patient outcomes. Tango Therapeutics Inc is dedicated to transforming the way cancer is treated by developing novel therapeutics that address the underlying genetic causes of the disease.


   Company Address: 201 Brookline Ave. Boston 2215 MA
   Company Phone Number: 320-4900   Stock Exchange / Ticker: NASDAQ TNGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABEO   -8.26%    
BBIO   -4.02%    
CUE        0.98% 
KYNB   -5.57%    
PFE   -4.46%    
RCUS   -16.64%    
• View Complete Report
   



Business Update

Tango Therapeutics, Inc. (NASDAQ TNGX), a distinguished player in the realm of biotechnology, stands at the...

Published Wed, Nov 6 2024 1:36 PM UTC

Tango Therapeutics: Advancing Precision Cancer Medicines with Promising Clinical Data and Strategic Growth Tango Therapeutics, Inc. (NASDAQ: TNGX), a distinguished player in the realm of biotechnology, stands at the forefront of the pursuit of precision cancer medicines. Recent advances have underscored the company s commitment to harnessing cutting-edge science to address t...
Business Update

Tango Therapeutics Halts Development of TNG348 Program Due to Safety Concerns

Published Thu, May 23 2024 12:15 PM UTC

In a recent announcement, Tango Therapeutics, a clinical-stage biotechnology company focused on advancing precision cancer medicines, revealed the discontinuation of its TNG348 program. The decision came as a result of emerging data from a dose escalation study, which showed significant liver toxicity among patients. This article aims to ly explore the facts surrounding this...
Product Service News

Tango Therapeutics Set to Present at Renowned Investor Conferences, Highlighting Cutting-Edge Research in Precision Cancer Medicines.

Published Wed, Mar 6 2024 12:00 PM UTC

Tango Therapeutics, a prominent clinical-stage biotechnology company, recently made an exciting announcement regarding its upcoming participation in several investor conferences. The company prides itself on its dedication to discovering and delivering precision cancer medicines, and this involvement in industry events demonstrates its commitment to advancing cancer research...
Shares

Tango Therapeutics' Bold Move: Stock Options Unleashed to Fuel Cancer Precision Revolution

Published Fri, Jan 5 2024 9:05 PM UTC



In a bid to revolutionize the field of precision cancer medicines, Tango Therapeutics, a clinical-stage biotechnology company, recently announced the granting of non-qualified stock options and restricted stock units (RSUs) to a new employee under their 2023 Inducement Plan. This move demonstrates Tango Therapeutics commitment to attracting top talent and driving ...
Clinical Study

Unleashing Precision Medicine: Tango Therapeutics Steps into Uncharted Territory with TNG348 in BRCA1/2-Mutant and HRD+ Cancers

Published Wed, Jan 3 2024 12:01 PM UTC

Tango Therapeutics Initiates Phase 1/2 Trial of TNG348 in BRCA1/2-Mutant and HRD+ CancersTango Therapeutics, a renowned clinical-stage biotechnology company specializing in precision cancer medicines, recently announced a major milestone in their research. The company revealed that the first patient has been dosed in the phase 1/2 trial evaluating TNG348 as a monotherapy an...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 65.17
Price to Sales (Expected) -
Price to Book 3.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 82.19
Working Capital Ratio 83.06
Leverage Ratio (MRQ) 0.05
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.89 $
Revenues (TTM) 0.36 $
Cash Flow (TTM) 0.79 $
Cash 11.13 $
Book Value 6.84 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -903,066
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.